The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Texas MPN Workshop 2021 | The latest clinical updates on navtemadlin for the treatment of MPNs
Srdan Verstovsek, MD, The University of Texas, MD Anderson Cancer Center, Houston, TX, shares the latest updates on the use of navtemadlin (also known as KRT-232 and AMG 232), an MDM2 inhibitor, for the treatment of myelofibrosis. Dr Verstovsek discusses how navtemadlin could be used as a treatment for patients who fail treatment with JAK inhibitors and briefly describes the drug’s mechanism of action. Navtemadlin is currently being trialled in an ongoing Phase II study in the second-line setting, and in the Phase III BOREAS study (NCT03662126) where it is being compared with the best available therapy for the treatment of patients who are relapsed or refractory to JAK inhibitors. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.
